engleski

Anticancer activity of two novel palladium (II) complexes in human leukemia cell lines

Effective treatments for human leukemias are still being developed, but so far none of them was found to be completely satisfying. It was recently reported that palladium complexes have a significant anti-cancer activity as well as lower toxici- ty and less side effects compared to some clinically used chemotherapeutics. Anti- cancer activities of two novel palladium (II) complexes [Pd(sac)(terpy)](sac)·4H2O and [PdCl(terpy)](sac)·2H2O were tested against three human leukemia cell lines: Jurkat, MOLT-4 and THP-1 and in comparison to cisplatin and adriamycin. Cytotoxic effect of two palladium (II) complexes, cisplatin and adriamycin was determined with the MTT viability assay, and IC50 values were calculated. Cell apoptosis was assesed with FITC-Annexin/PI staining for flow cytometry and fluo- rescent microscopy, and caspase-3 colorimetric assay. Specific apoptotic pathway was elucidated by caspase-8 and -9 colorimetric assays. Furthermore, PARP cleav- age and p53 activity were determined by western blot to elucidate whether treat- ments induce apoptotic or necrotic response. Both complexes exhibited a signifi- cant dose-dependent anti-growth effect in vitro, more powerful than cisplatin and less effective than adriamycin, but with less side effects. The complexes predomi- nately induced apoptosis, but necrosis was also observed. In vitro results have shown that palladium (II) complexes may be a potential anti-cancer agents for treating human leukemias, but further analysis to determine putative mechanism of action and in vivo studies on animal models are essential.

human leukemia cell lines; palladium comlexes; anti-cancer activity; cisplatin; apoptosis; necrosis

nije evidentirano